Skip to main content
[Preprint]. 2023 Aug 3:rs.3.rs-3168149. [Version 1] doi: 10.21203/rs.3.rs-3168149/v1

Figure 1: Dexamethasone modulates cytokine and immune cell gene expression in the blood of patients with COVID-19.

Figure 1:

a, The introduction of dexamethasone (Dex) as standard of care for critically ill patients hospitalized with COVID-19 based on the results of the RECOVERY trial. Blood and tracheal aspirate (TA) samples were collected from intubated patients enrolled either before or after this change. b, Included patients and time points per analysis. A single sample was used per patient. Each patient was either treated with Dex (orange) or not (blue). Samples used in DIABLO analysis (Figure 2) are the overlap in PBMC bulk RNA sequencing and plasma cytokine rows. c, Individual plots of log-transformed significant cytokines IL-6, IL-10, and interferon gamma (IFN-gamma) (Wilcoxon test, adjusted p-value < .1). N = 23 Dex, N = 15 NoDex. d, Volcano plot of differential gene expression of PBMC RNA-seq data. N = 10 Dex, N = 11 NoDex.